Bayer’s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer
American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019